Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

Core Viewpoint - Keros Therapeutics, Inc. is advancing its clinical programs, receiving positive FDA feedback for its KER-050 program, and plans to discuss its pipeline in an upcoming conference call [2][3]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional TGF-ß signaling [3]. - The company is a leader in understanding the TGF-ß family of proteins, which regulate the growth and maintenance of various tissues [3]. - Keros' lead product candidate, KER-050 (elritercept), targets low blood cell counts in patients with myelodysplastic syndromes (MDS) and myelofibrosis [3]. - The second product candidate, KER-012 (cibotercept), is aimed at treating pulmonary arterial hypertension (PAH) and cardiovascular disorders [3]. - Keros is also developing KER-065 for obesity and neuromuscular diseases [3]. Recent Developments - Keros received positive feedback from the FDA regarding the design and endpoints for the pivotal Phase 3 clinical trial of KER-050 in MDS patients [2]. - The company expects to complete enrollment for its ongoing Phase 2 TROPOS trial of KER-012 in PAH patients by the fourth quarter of 2024 [2]. Upcoming Events - Keros will host a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time [1][2].